Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) shares were down 5.2% during trading on Monday . The stock traded as low as $10.8435 and last traded at $10.8435. 291 shares traded hands during trading, a decline of 97% from the average session volume of 9,230 shares. The stock had previously closed at $11.44.
Santen Pharmaceutical Stock Performance
The firm has a 50 day simple moving average of $11.97 and a two-hundred day simple moving average of $11.71.
About Santen Pharmaceutical
Santen Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company focused on ophthalmology. The company researches, develops, manufactures and commercializes prescription eye-care medicines and related products for conditions affecting vision and ocular health.
Its portfolio includes treatments for glaucoma and ocular hypertension, dry eye disease, retinal disorders, eye infections and allergies, as well as other ophthalmic conditions. Santen also conducts research in areas such as regenerative medicine and other therapies intended to address unmet needs in eye care.
Founded in Japan in 1890, Santen has expanded beyond its domestic market and serves patients and healthcare professionals across Asia, Europe and other international markets.
Featured Articles
- Five stocks we like better than Santen Pharmaceutical
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
- 3 Retail Dips Backed by Rising Consumer Demand
- 3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
